Pardes Biosciences, Inc.

About Pardes Biosciences, Inc.

Pardes Biosciences, Inc. was a clinical-stage biopharmaceutical company established in 2020 with a strategic focus on developing therapeutics for pandemic-level diseases. The company was founded by Uri Lopatin, M.D., who brought significant experience from roles at Gilead Sciences, Schering Plough, and as a founder of Assembly Pharma, channeling his background in virology and drug development to address the urgent needs presented by the COVID-19 pandemic.

The company's core business was centered on the discovery and development of novel oral antiviral drugs. Its primary operational strategy involved leveraging structure-based drug design and a proprietary covalent chemistry platform to create its product candidates. The business model was that of a pre-revenue biotechnology firm, dependent on securing capital from investors to fund its research and development pipeline, with the ultimate goal of commercializing a successful therapeutic or partnering with larger pharmaceutical entities.

Pardes Biosciences' lead product candidate was PBI-0451 (later named pomotrelvir), an oral antiviral designed to treat and prevent SARS-CoV-2 infections. The drug functioned as a main protease (Mpro) inhibitor, targeting a crucial protein necessary for the virus's replication. A key feature of this approach was that the Mpro protein is highly conserved across various coronaviruses, suggesting the potential for PBI-0451 to be effective against emerging variants and possibly future coronavirus threats. The intended benefit was to offer an unboosted, stand-alone oral therapy that could be easily administered to patients outside of a hospital setting.

The company achieved several key milestones in its short history. It went public in December 2021 through a merger with a special purpose acquisition company (SPAC), FS Development Corp. II, raising approximately $274 million to advance its clinical programs. PBI-0451 progressed into a Phase 1 human trial in August 2021 and subsequently into Phase 2 studies. However, the company's trajectory shifted dramatically in April 2023 when the Phase 2 trial for pomotrelvir failed to demonstrate superiority over a placebo in clearing the virus. This critical setback led to the suspension of the program and a search for strategic alternatives. Consequently, in August 2023, Pardes was acquired by MediPacific, an entity controlled by key shareholders including Foresite Capital, and its stock was subsequently delisted from Nasdaq.